Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

406
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
406
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

194
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
194
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

553
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
553
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

677
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
677
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

150
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
150
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

317
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
317

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mapping the Use of Real-World Evidence Across the EU Health Technology Assessment Regulation: Methodological Considerations, Challenges, and Opportunities for Harmonization.

Journal of market access & health policy·2026
Same author

Development and implementation of a digital health intervention in routine care for long COVID patients: a comprehensive synopsis.

Health and social care delivery research·2025
Same author

Transportability of nonlocal real-world evidence and its relevance to health technology assessment: a primer.

Journal of comparative effectiveness research·2025
Same author

Quantitative Bias Analysis for Single-Arm Trials With External Control Arms.

JAMA network open·2025
Same author

Remotely Delivered Video Interaction Guidance for Families of Children With an Intellectual Disability Referred to Specialist Mental Health Services: Protocol for a Feasibility Randomized Controlled Trial.

JMIR research protocols·2024
Same author

Trajectories of functional limitations, health-related quality of life and societal costs in individuals with long COVID: a population-based longitudinal cohort study.

BMJ open·2024
Same journal

Access in all areas? A round-up of developments in market access and health technology assessment: part 15.

Journal of comparative effectiveness research·2026
Same journal

Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy.

Journal of comparative effectiveness research·2026
Same journal

Considerations for assessing the feasibility of network meta-analysis of seasonal vaccines.

Journal of comparative effectiveness research·2026
Same journal

Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review.

Journal of comparative effectiveness research·2026
Same journal

Acthar Gel treatment in patients with rheumatoid arthritis, systemic lupus erythematosus, or dermatomyositis/polymyositis: analysis of physician-reported charts.

Journal of comparative effectiveness research·2026
Same journal

Use of intracardiac echocardiography and three-dimensional mapping during catheter ablation for atrial fibrillation is associated with reduced complications: a retrospective analysis of United States Medicare Fee-For-Service Database.

Journal of comparative effectiveness research·2026
See all related articles

Related Experiment Video

Updated: Jan 16, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K

Estimating per-protocol effects in external comparator analyses using real-world data.

Alind Gupta1,2, Evie Merinopoulou3, Stephen J Duffield4

  • 1Fifty1 AI LabsVancouver, British Columbia. V6H 3Y4 Canada.

Journal of Comparative Effectiveness Research
|October 6, 2025
PubMed
Summary
This summary is machine-generated.

Estimating per-protocol effects in oncology trials using external comparator arms (ECAs) is challenging due to adherence differences. This study proposes a target trial emulation approach to improve interpretation and guide future research.

Keywords:
adherencecomparative effectivenessexternal controlsper-protocol effectstarget trial emulation

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.5K
Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

477

Related Experiment Videos

Last Updated: Jan 16, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.5K
Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

477

Area of Science:

  • Oncology Research
  • Clinical Trial Design
  • Biostatistics

Background:

  • Single arm trials with external comparator arms (ECAs) support novel oncology therapy evidence when randomized trials are infeasible.
  • Interpreting intention-to-treat effects in ECA studies is difficult due to adherence variations between trial and ECA.
  • Per-protocol effect estimation is crucial for accurate interpretation in such scenarios.

Purpose of the Study:

  • To describe an approach for estimating per-protocol effects in external comparator arm (ECA) studies.
  • To utilize the target trial emulation framework for study design and analysis in ECA settings.
  • To identify challenges and solutions for implementing per-protocol effect estimation in ECAs.

Main Methods:

  • Employed the target trial emulation framework for study design and analysis.
  • Utilized results from an exploratory case study (TBASEL) for demonstration.
  • Focused on protocol specification, data suitability, and analysis considerations.

Main Results:

  • Presented a novel approach for per-protocol effect estimation in ECA studies.
  • Highlighted key challenges in protocol specification, data suitability, and analysis.
  • Offered potential solutions and identified future research opportunities.

Conclusions:

  • The target trial emulation framework offers a structured approach to estimate per-protocol effects in ECA studies.
  • Addressing challenges in protocol specification, data, and analysis is vital for reliable per-protocol effect estimation.
  • This methodology can enhance the interpretation of novel therapy effectiveness in oncology research.